Kevin M. Kalinsky

GPNMB overexpression- a marker of resistance to CDK4/6 inhibitors

This study identifies GPNMB overexpression as a marker of resistance to CDK4/6 inhibitors in estrogen receptor-positive breast cancer.

Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer

This study shows that continuing CDK4/6 inhibitors and adding CDK2 inhibitors slows growth of drug-resistant breast cancer by delaying cell cycle progression and reducing E2F transcription.

Pre-clinical validation of an RNA-based precision oncology platform for patient-therapy alignment in a diverse set of human malignancies resistant to standard treatments

The paper validates an RNA-based platform for predicting drug sensitivity in treatment-resistant cancers using patient-derived xenograft models and multi-protein therapies.

Reconstructing tumor trajectories during therapy through integration of multiple measurement modalities.

The paper reconstructs tumor size trajectories during therapy by integrating multiple measurement modalities to identify distinct patterns of tumor response and resistance.